JP2005519908A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519908A5
JP2005519908A5 JP2003562099A JP2003562099A JP2005519908A5 JP 2005519908 A5 JP2005519908 A5 JP 2005519908A5 JP 2003562099 A JP2003562099 A JP 2003562099A JP 2003562099 A JP2003562099 A JP 2003562099A JP 2005519908 A5 JP2005519908 A5 JP 2005519908A5
Authority
JP
Japan
Prior art keywords
compound
methyl
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003562099A
Other languages
English (en)
Japanese (ja)
Other versions
JP4213595B2 (ja
JP2005519908A (ja
Filing date
Publication date
Priority claimed from GBGB0201508.9A external-priority patent/GB0201508D0/en
Application filed filed Critical
Publication of JP2005519908A publication Critical patent/JP2005519908A/ja
Publication of JP2005519908A5 publication Critical patent/JP2005519908A5/ja
Application granted granted Critical
Publication of JP4213595B2 publication Critical patent/JP4213595B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003562099A 2002-01-23 2003-01-22 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド Expired - Fee Related JP4213595B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201508.9A GB0201508D0 (en) 2002-01-23 2002-01-23 Organic compounds
PCT/EP2003/000613 WO2003062220A1 (en) 2002-01-23 2003-01-22 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008208640A Division JP5027076B2 (ja) 2002-01-23 2008-08-13 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド

Publications (3)

Publication Number Publication Date
JP2005519908A JP2005519908A (ja) 2005-07-07
JP2005519908A5 true JP2005519908A5 (enExample) 2005-12-22
JP4213595B2 JP4213595B2 (ja) 2009-01-21

Family

ID=9929594

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003562099A Expired - Fee Related JP4213595B2 (ja) 2002-01-23 2003-01-22 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド
JP2008208640A Expired - Fee Related JP5027076B2 (ja) 2002-01-23 2008-08-13 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008208640A Expired - Fee Related JP5027076B2 (ja) 2002-01-23 2008-08-13 N−フェニル−2−ピリミジン−アミン誘導体のn−オキシド

Country Status (15)

Country Link
US (5) US7557105B2 (enExample)
EP (3) EP1783126A3 (enExample)
JP (2) JP4213595B2 (enExample)
KR (2) KR20070058019A (enExample)
CN (2) CN101468984A (enExample)
AT (1) ATE380807T1 (enExample)
BR (1) BR0307058A (enExample)
CA (1) CA2474104C (enExample)
DE (1) DE60318013T2 (enExample)
ES (2) ES2503734T3 (enExample)
GB (1) GB0201508D0 (enExample)
IL (2) IL162979A (enExample)
MX (1) MXPA04007130A (enExample)
PT (2) PT2194049E (enExample)
WO (1) WO2003062220A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
ATE454152T1 (de) * 2003-06-13 2010-01-15 Novartis Pharma Gmbh 2-aminopyrimidin-derivate als raf-kinase-hemmer
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) * 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
ME00011A (me) * 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
EP2068835A2 (en) * 2006-09-01 2009-06-17 Teva Pharmaceutical Industries Ltd. Imatinib compositions
US20080207904A1 (en) * 2006-10-26 2008-08-28 Macdonald Peter Imatinib base, and imatinib mesylate and processes for preparation thereof
EP1988089A1 (en) * 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
CN101245061B (zh) * 2007-02-13 2012-09-19 天津天士力集团有限公司 N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物,制备方法及其用途
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
JP5710251B2 (ja) 2007-06-07 2015-04-30 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規ヘテロ環化合物およびその使用
EP2166860B1 (en) 2007-06-07 2016-09-21 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
EP2086520A1 (en) * 2007-09-25 2009-08-12 Teva Pharmaceutical Industries Ltd. Imatinib compositions
CN101848895B (zh) * 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
WO2009118108A1 (en) * 2008-03-26 2009-10-01 Merck Patent Gmbh Method of long term storage of substrate-coupled beads
CN101417995B (zh) * 2008-11-21 2012-06-06 陈依军 苯氧基嘧啶衍生物及其制备方法和用途
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
KR20250024102A (ko) 2015-02-25 2025-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE4444288A1 (de) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Verwendung von Weihrauch zur Behandlung der Alzheimer-Krankheit
NZ302926A (en) * 1995-02-28 1998-10-28 Hoechst Marion Roussel Inc Composition for use as antihistamines comprising piperidinoalkanol derivatives and inert ingredients
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments

Similar Documents

Publication Publication Date Title
JP2005519908A5 (enExample)
CA2474104A1 (en) N-oxides of n-phenyl-2-pyrimidine-amine derivatives
JP5656874B2 (ja) Pde9阻害剤として使用されるアミノヘテロ環化合物
JP2008509187A5 (enExample)
EP0960106B1 (en) 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4)
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
JP2008513498A5 (enExample)
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2002520416A5 (enExample)
MX2007005644A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
RU2004106783A (ru) Производные 4-амино-6-фенилпирроло[2, 3] пиримидина
CA2416274A1 (en) N-phenyl-2-pyrimidine-amine derivatives
JP2005511699A5 (enExample)
JP2016507581A (ja) Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
PT2420491E (pt) Compostos de piperidina 3,5-substituída como inibidores de renina
JP2005508923A5 (enExample)
JP2002030084A5 (enExample)
JP2006501201A5 (enExample)
JP2020529995A (ja) 行動の変化の治療方法
JP2005532397A5 (enExample)
JPH06500099A (ja) Cns疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用
JP2003516994A5 (enExample)
JP2003529597A5 (enExample)
US8716292B2 (en) Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
RU2007101522A (ru) Диарилметилпиперазиновые производные, их получение и применение